At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ADIL Adial Pharmaceuticals
Trading 04-09 10:00:02 EDT
1.59
-0.06
-3.64%
High1.65
Low1.58
Vol36.81K
Open1.62
D1 Closing1.65
Amplitude4.24%
Mkt Cap2.27M
Tradable Cap2.08M
Total Shares1.43M
T/O59.85K
T/O Rate2.81%
Tradable Shares1.31M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Adial commends bipartisan H.R. 7091 to expand veterans’ access to emerging AUD therapies
Adial Pharmaceuticals Signs an Exclusive Ad04 Collaboration Framework With Molteni Farmaceutici for Europe Which Anticipates Nearly $60 Million in Potential Royalties and Milestones Upon Execution of a Definitive Agreement
Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.